Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Raily Aesthetic Medicine International Holdings Limited ( (HK:2135) ) has shared an announcement.
Raily Aesthetic Medicine International Holdings Limited has scheduled a board meeting for 27 March 2026 to review and approve the audited annual results for the year ended 31 December 2025. The board will also consider whether to declare, recommend or pay a dividend, which could affect shareholder returns and signal management’s confidence in the Group’s financial performance.
The announcement also confirms the current composition of the board, comprising three executive directors and three independent non-executive directors, underscoring the company’s adherence to Hong Kong corporate governance requirements. Investors will be watching the upcoming results and any dividend decision for indications of the Group’s operational health and its positioning in the competitive aesthetic medicine market.
The most recent analyst rating on (HK:2135) stock is a Hold with a HK$0.15 price target. To see the full list of analyst forecasts on Raily Aesthetic Medicine International Holdings Limited stock, see the HK:2135 Stock Forecast page.
More about Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited is a Cayman Islands–incorporated company listed in Hong Kong, operating in the aesthetic medicine sector through its subsidiaries. The Group focuses on providing medical aesthetic services in mainland China, positioning itself within the broader healthcare and beauty services industry.
Average Trading Volume: 569,886
Technical Sentiment Signal: Sell
Current Market Cap: HK$75.76M
See more data about 2135 stock on TipRanks’ Stock Analysis page.